Bulk anti-Human RNase L (2E9) Antibody

Human, Hamster, Primate

RNase L

>1mg/ml

Mouse IgG1 Kappa

Mouse

Aggregation level ≤ 5%

Purified, full-length, recombinant, human RNaseL produced in insect cells.

ICH3002-100ml

Q05823;P61221

Blue ice

This is a mouse monoclonal antibody, clone 2E9 (Mouse IgG1, kappa), raised against human RNase L and validated for reactivity with human, hamster and primate samples. It is offered as a bulk, research-use-only reagent suited to laboratories that need larger, consistent quantities for repeated or scaled-up experiments. The clone is validated across multiple standard formats, including ELISA, paraffin-section immunohistochemistry (IHC-P) and Western blotting, making it appropriate for detecting, localising and quantifying RNase L protein in lysates and fixed tissue. Because RNase L is an intracellular, cytosolic effector of the interferon antiviral response rather than a cell-surface immunotherapy target, this antibody is primarily an analytical and target-characterisation tool rather than a function-blocking or depleting in-vivo therapeutic. As an ichor.bio research antibody it is manufactured to support rigorous, reproducible work, with low-endotoxin, bulk-format supply intended for demanding academic and industrial research programmes. Investigators should validate the clone in their own system and application before relying on it for quantitative or publication-grade results. RNase L (2-5A-dependent ribonuclease; gene RNASEL, UniProt Q05823) is a latent cytosolic endoribonuclease and a central effector of the interferon-induced innate antiviral response. During viral infection, double-stranded RNA activates interferon-inducible 2'-5'-oligoadenylate synthetases (OAS), which polymerise ATP into short 2'-5'-linked oligoadenylates (2-5A). 2-5A binds the ankyrin-repeat domain of RNase L, driving its dimerisation and activating the C-terminal ribonuclease. Activated RNase L cleaves single-stranded viral and cellular RNA at UU/UA dinucleotides, limiting viral replication, and the resulting small RNA fragments can engage RIG-I-like receptors to amplify type I interferon signalling and can trigger apoptotic cell death. Through these activities RNase L contributes to antiviral defence, RNA turnover and cytoskeletal-associated innate responses. RNASEL has also been studied as a candidate hereditary prostate cancer susceptibility gene (HPC1).

2-5A-dependent RNase, Ribonuclease 4, Ribonuclease L, 2'-5'-oligoadenylate-binding protein, HuHP68, RNase L inhibitor, Ribonuclease 4 inhibitor, RNS4I, 2-5A-dependent ribonuclease, ATP-binding cassette sub-family E member 1, RNS4, ABCE1, RLI, RNASEL1

2.00E+09

Recognizes an interferon-induced latent endoribonuclease (Mr ~83 kDa) activated by 2-5A in the antiviral response.

This monoclonal antibody was purified using Protein A

This antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.

This low endotoxin antibody is stable when stored at 2-8°C for at least four (4) weeks. For long-term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

ELISA, IHC Paraffin, in vivo, Western Blotting

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Can I order clone 2E9 in bulk?

A: Yes — 2E9 is manufactured in scalable milligram to gram quantities for bulk and high-throughput experiments.

Q: Is clone 2E9 suitable for in vivo RNase L studies?

A: Yes, it is supplied low-endotoxin and in vivo-grade for in vivo and in vitro RNase L work.

Q: What does clone 2E9 target?

A: It is a monoclonal antibody that binds RNase L; for research use only.